Berlex Voluntarily Recalls Ultravist(R) Injection 370 mgI/mL
Berlex Voluntarily Recall Its X-ray Contrast Agent Ultravist Injection. Berlex, Inc., a US affiliate of Schering AG, Germany, is voluntarily recalling all lots of its X-ray contrast agent Ultravist Injection 370 mgI/mL (iopromide injection), as part of a worldwide recall, due to the potential that particulate matter in conjunction … [Read more...] about Berlex Voluntarily Recalls Ultravist(R) Injection 370 mgI/mL
Betaseron Hepatoxicity Reminder
Betaseron Pertains To Hepatic Toxicity. Berlex, Inc. reminded healthcare professionals of the prescribing information for ‘Betaseron’ (interferon beta-1b) as it pertains to hepatic toxicity. ‘Betaseron’ is approved for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical … [Read more...] about Betaseron Hepatoxicity Reminder
